Edition:
India

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

8.46USD
22 Jun 2018
Change (% chg)

$0.31 (+3.80%)
Prev Close
$8.15
Open
$8.25
Day's High
$8.52
Day's Low
$8.12
Volume
124,523
Avg. Vol
26,233
52-wk High
$13.16
52-wk Low
$5.28

Chart for

About

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid... (more)

Overall

Beta: --
Market Cap(Mil.): $206.16
Shares Outstanding(Mil.): 24.60
Dividend: --
Yield (%): --

Financials

BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54

* OVID THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE PROGRESS

09 May 2018

BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45

* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS

30 Mar 2018

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME

15 Mar 2018

Earnings vs. Estimates